Skip to main
CV
CV logo

CapsoVision Inc (CV) Stock Forecast & Price Target

CapsoVision Inc (CV) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CapsoVision Inc. has achieved significant revenue growth, generating nearly $12 million in 2024 from the CapsoCam Plus, which has been utilized in over 135,000 procedures since its launch. The company's ongoing success is attributed to market share gains and consistent year-over-year revenue increases since the commencement of its U.S. operations. Furthermore, the continued development of the CapsoColon 3D for large intestine imaging positions CapsoVision favorably within the expanding medical technology sector focused on gastrointestinal health.

Bears say

CapsoVision Inc faces significant challenges in revenue growth and profitability due to potential resistance from physicians, hospitals, or patients regarding the retrieval of its endoscopic capsule after use. Additionally, risks associated with manufacturing disruptions, negative clinical outcomes, or product recalls could adversely affect investor confidence and overall revenue. Regulatory hurdles, such as the CE mark restrictions, may further limit the sales potential of CapsoCam Plus, particularly as the company seeks to expand into pediatric applications and fully digestible methodologies.

CapsoVision Inc (CV) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CapsoVision Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CapsoVision Inc (CV) Forecast

Analysts have given CapsoVision Inc (CV) a Buy based on their latest research and market trends.

According to 1 analysts, CapsoVision Inc (CV) has a Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CapsoVision Inc (CV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.